enGene (ENGN) Projected to Post Quarterly Earnings on Monday

enGene (NASDAQ:ENGN) is expected to be posting its Q1 2026 results before the market opens on Monday, March 9th. Analysts expect enGene to post earnings of ($0.55) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

enGene (NASDAQ:ENGN) last issued its earnings results on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Price Performance

Shares of NASDAQ ENGN opened at $8.68 on Friday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $581.47 million, a price-to-earnings ratio of -3.79 and a beta of -0.29. enGene has a twelve month low of $2.65 and a twelve month high of $12.25. The business has a 50 day simple moving average of $9.58 and a 200-day simple moving average of $8.04.

Hedge Funds Weigh In On enGene

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cresset Asset Management LLC acquired a new stake in shares of enGene in the second quarter valued at $36,000. Paloma Partners Management Co acquired a new stake in enGene in the 2nd quarter valued at about $38,000. Raymond James Financial Inc. lifted its holdings in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of enGene by 153.3% during the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after purchasing an additional 35,327 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ENGN shares. Citizens Jmp lifted their price objective on shares of enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 12th. Jefferies Financial Group started coverage on shares of enGene in a research report on Friday, January 30th. They issued a “buy” rating and a $28.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of enGene in a research report on Wednesday, December 3rd. Finally, UBS Group increased their price objective on shares of enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, enGene currently has an average rating of “Moderate Buy” and an average price target of $23.29.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.